4.3 Alabama Prescription Drug Monitoring Program (PDMP): Dispenser Daily Reporting & Prescriber Query Mandates

4.3 Alabama Prescription Drug Monitoring Program (PDMP): Dispenser Daily Reporting & Prescriber Query Mandates

[!CAUTION] Core Exam Concept: The Alabama Prescription Drug Monitoring Program (PDMP) is an electronic clinical database established under the Code of Alabama 1975 § 20-2-210 et seq. to track the dispensing of controlled substances. A critical jurisprudence distinction tested frequently on the MPJE is that the Alabama PDMP is administered and maintained by the Alabama Department of Public Health (ADPH)—NOT the Alabama State Board of Pharmacy. The database captures all controlled substances in Schedules II, III, IV, and V, including Gabapentin, which has been classified as a Schedule V controlled substance under Alabama law since November 18, 2019. Licensed dispensers must transmit dispensing data electronically at least once daily (by 11:59 p.m.), and must submit a zero-report if no controlled substances were dispensed during a business day. Prescribers face strict mandatory query tiers under Alabama Board of Medical Examiners rules based on daily Morphine Milligram Equivalents (MME).

The PDMP serves as Alabama's primary frontline weapon against diversion, doctor-shopping, and polypharmacy overdose deaths. Pharmacists must understand both their operational reporting duties as dispensers and their clinical gatekeeping duties when querying patient drug histories.

---

Statutory Authority and Administration

+-----------------------------------------------------------------------------------------+
|                     Alabama PDMP Statutory & Administrative Overview                    |
+-----------------------------------------------------------------------------------------+
|  GOVERNING STATUTE:     Code of Alabama 1975 § 20-2-210 et seq.                         |
|  REGULATORY AGENCY:     Alabama Department of Public Health (ADPH)                      |
|                         (Exam Trap: NOT the Alabama State Board of Pharmacy!)           |
|  REPORTING FREQUENCY:   At least ONCE DAILY (by 11:59 p.m.)                             |
|  ZERO-REPORTING:        MANDATORY on business days with zero controlled fills           |
|  SCHEDULES MONITORED:   Schedules II, III, IV, and V (including Gabapentin C-V)         |
|  AUTHORIZED USERS:      Licensed prescribers, pharmacists, law enforcement (court order)|
+-----------------------------------------------------------------------------------------+

Administrative Oversight: ADPH vs. ALBOP

On the MPJE, a standard distractor asserts that the Alabama Board of Pharmacy operates the state monitoring database. In Alabama, the Department of Public Health holds statutory responsibility for administering the PDMP database, managing user credentials, analyzing prescribing trends, and maintaining cybersecurity safeguards. The Board of Pharmacy cooperates with the ADPH by enforcing compliance with dispensing rules and disciplining licensees who fail to report or who access the system unlawfully.

Controlled Substances Monitored

Under Ala. Code § 20-2-213, all controlled substances dispensed to outpatient human patients in Alabama must be reported:

• Schedule II Controlled Substances: Opioids (oxycodone, hydrocodone, fentanyl, morphine, methadone) and stimulants (amphetamine salts, methylphenidate).
• Schedule III Controlled Substances: Buprenorphine formulations, anabolic steroids, dronabinol, ketamine, intermediate-acting barbiturates.
• Schedule IV Controlled Substances: Benzodiazepines (alprazolam, clonazepam, diazepam), sedative-hypnotics (zolpidem, eszopiclone), carisoprodol (Soma), tramadol.
• Schedule V Controlled Substances: Pregabalin (Lyrica), low-dose codeine cough syrups (e.g., promethazine with codeine), diphenoxylate/atropine (Lomotil), and Gabapentin.

The Alabama Gabapentin Scheduling Rule

• Effective Date: November 18, 2019.
• Statutory Action: The Alabama State Board of Pharmacy and the Alabama Legislature transferred gabapentin from non-controlled legend status to Schedule V of the Alabama Uniform Controlled Substances Act.
• Clinical Rationale: Gabapentin exhibits significant synergistic abuse liability when combined with opioids, producing intense euphoria while severely exacerbating opioid-induced respiratory depression. Gabapentin diversion had escalated dramatically in illicit drug markets across the Southeast.
• Legal Ramifications: Under Alabama law, gabapentin is fully treated as a Schedule V controlled substance:
  1. Every gabapentin prescription must be reported daily to the Alabama PDMP.
  2. Refills are restricted to a maximum of 5 refills within 6 months from the date of issue (matching Schedule III–IV refill limits under Alabama rule).
  3. Controlled substance prescription blank standards, storage rules, and transfer limitations apply.
  4. Mid-level prescribers (CRNPs, CNMs, PAs) must hold an active QACSC to prescribe gabapentin in Alabama.

---

Dispenser Reporting Requirements

Every pharmacy licensed by the Alabama State Board of Pharmacy that dispenses controlled substances to outpatients in Alabama must report its transactions electronically to the ADPH PDMP.

Daily Reporting Frequency

• Transmission Timeline: Controlled substance dispensings must be submitted electronically to the database at least once daily (every 24 hours). The statutory reporting cutoff is 11:59 p.m. on the calendar day following the dispensing event.
• Data Standardization: Records must be transmitted using the American Society for Automation in Pharmacy (ASAP) telecommunications format for prescription monitoring programs.
• Mandatory Data Fields: Dispenser DEA number, prescriber DEA number and ACSC number, date prescription written, date prescription filled, prescription number, whether new fill or refill number, National Drug Code (NDC) of the medication, metric quantity dispensed, estimated days supply, patient full legal name, patient physical residential address, patient date of birth, and method of payment (cash, commercial third-party insurance, Alabama Medicaid, Medicare).

The Mandatory Zero-Reporting Requirement

• If a licensed retail, specialty, or closed-door outpatient pharmacy is open for business on a given calendar day but dispenses zero controlled substances (Schedules II through V), the supervising pharmacist must ensure an electronic zero-report (zero-fill file) is transmitted to the ADPH PDMP by 11:59 p.m.
• Submitting a zero-report affirmatively documents that the pharmacy was operational and did not experience a data transmission outage or neglect its statutory reporting obligations.

Reporting Exemptions

Under Ala. Code § 20-2-213, reporting is not required for:

1. Direct administration of a controlled substance to an inpatient in a licensed acute care hospital.
2. Direct administration in an emergency department or surgical ambulatory center for immediate stabilization.
3. Dispensing of medication samples by a licensed physician in accordance with ALBME medical rules.
4. Wholesale distribution of controlled substances between licensed manufacturers and distributors (monitored under DEA ARCOS systems).

---

Prescriber Query Mandates under ALBME Rules

Under Alabama Administrative Code Rule 540-X-4-.09(5) (promulgated by the Alabama Board of Medical Examiners), prescribers are held to strict, tiered requirements for querying the Alabama PDMP based on daily Morphine Milligram Equivalents (MME) or Long-acting Morphine Equivalents (LME):

+-----------------------------------------------------------------------------------------+
|                  ALBME Tiered Prescriber PDMP Query Mandates                            |
+-----------------------------------------------------------------------------------------+
|  TIER 1: < 30 MME / 3 LME per day                                                       |
|  • Regulatory Standard: Query consistent with good medical practice                     |
|  • Prescriber discretion based on clinical presentation and risk history                |
|                                                                                         |
|  TIER 2: > 30 MME / 3 LME per day                                                       |
|  • Regulatory Standard: MANDATORY query at least TWICE PER YEAR (every 6 months)        |
|  • Chart Requirement:   Must document query and clinical assessment in medical record   |
|                                                                                         |
|  TIER 3: > 90 MME / 5 LME per day                                                       |
|  • Regulatory Standard: MANDATORY query ON THE EXACT DATE OF ISSUANCE EVERY TIME        |
|  • Chart Requirement:   Must document query before issuing each prescription            |
+-----------------------------------------------------------------------------------------+

Analysis of Query Tiers

1. Dosages < 30 MME / 3 LME per day: The prescriber is expected to query the PDMP consistent with good clinical practice (e.g., at therapy initiation or when clinical changes occur), but routine mandatory intervals are left to professional medical judgment.
2. Dosages > 30 MME / 3 LME per day: When maintenance therapy exceeds 30 MME/day, the prescriber must query the PDMP at least twice per year (at minimum every six months). The prescriber must place a copy of the PDMP report or a written notation summarizing the query findings directly into the patient's permanent medical chart.
3. Dosages > 90 MME / 5 LME per day: For high-risk opioid regimens exceeding 90 MME/day, the prescriber must query the PDMP on the exact date every single time an opioid prescription is issued. Writing an order for >90 MME/day without accessing the PDMP that same day constitutes a direct regulatory violation punishable by medical board disciplinary action.

Statutory Exemptions from Prescriber Query Mandates

Prescribers are exempt from the mandatory PDMP query intervals under three specific clinical conditions:

• Inpatient Hospital Treatment: Medications ordered and administered within a licensed inpatient healthcare facility.
• Hospice Patients: Patients enrolled in a certified hospice program, provided the prescriber writes the word "HOSPICE" clearly on the face of the prescription blank.
• Nursing Home Residents: Patients residing in a licensed skilled nursing facility or intermediate care nursing home where medication administration is strictly controlled by licensed nursing staff.

---

Pharmacist Authorized Access, Due Diligence & Confidentiality

While prescribers have legally mandated query schedules based on dosage tiers, Alabama pharmacists possess statutory authority to access the PDMP to execute their corresponding responsibility under federal and state law.

Clinical Red Flags Detected via the PDMP

Pharmacists should query the PDMP when evaluating initial controlled therapy, dosage escalations, or suspicious presentations to identify:

• Doctor Shopping: Multiple prescribers issuing controlled substance orders for the same or similar therapeutic indications within overlapping timeframes.
• Pharmacy Hopping: A patient filling controlled prescriptions at multiple unrelated community pharmacies across town or across county lines.
• Overlapping Fills and Early Refill Frequency: Calculating the patient's actual proportion of days covered (PDC) and identifying recurrent demands for early dispensing.
• Polypharmacy Cocktails: Concomitant fills for the "Holy Trinity" (opioid + benzodiazepine + carisoprodol) or concurrent gabapentinoids and sedatives from different practitioners.
• Payment Inconsistencies: Cash transactions occurring concurrently with third-party insurance fills.

Strict Confidentiality and Criminal Penalties for Unauthorized Access

• Protected Health Information: PDMP data is confidential, privileged medical information and is not a public record subject to open records requests.
• Authorized Clinical Purpose Only: A pharmacist or pharmacy intern may query the PDMP solely and exclusively for the purpose of providing pharmaceutical care to a bona fide patient who has presented a prescription to the pharmacy or who has an active established patient profile at that pharmacy.
• Prohibited Snooping: Accessing PDMP records for family members, spouses, coworkers, friends, celebrities, neighbors, or oneself without a bona fide clinical dispensing encounter is strictly illegal.
• Criminal and Administrative Penalties: Under Ala. Code § 20-2-215, intentional unauthorized access, dissemination, or disclosure of PDMP data is a Class A misdemeanor (and may constitute a felony under computer privacy statutes). Violators face up to 1 year in jail, substantial monetary fines, permanent revocation of PDMP user credentials, and formal disciplinary proceedings before the Alabama State Board of Pharmacy resulting in license suspension or revocation.